
    
      This was a stratified two-stage, single-arm, phase 2 study of treatment with everolimus in
      patients with advanced (unresectable or metastatic) pancreatic neuroendocrine tumor (NET)
      after failure of cytotoxic chemotherapy.

      Stratum 1, consisted of patients not receiving chronic Octreotide Depot therapy, will receive
      everolimus monotherapy at 10 mg/day.

      Stratum 2, consisting of patients with tumors that have progressed during Octreotide Depot
      treatment will continue their entry dose of Octreotide Depot plus everolimus 10 mg/day.
    
  